Am J Clin Pathol

1. ZHAO Y, Hajjali I, Ju Y, Carrillo L, et al
   Composite lymphoma composed of follicular lymphoma and nodal T-follicular helper cell lymphoma: report of 3 cases highlighting histopathologic zonation of each neoplastic component.
   Am J Clin Pathol. 2026;165:aqag012.
   

   >> Share

   
   

   
   Blood

2. ZAMMAR G, Cheah CY
   Pretransplant promise for PD-1 in Hodgkin lymphoma.
   Blood. 2026;147:1015-1017.
   

   >> Share

   
   
3. CROMBIE JL, Ahmed S, Frigault MJ, Hunter BD, et al
   Real-world outcomes for lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
   Blood. 2026 Mar 3:blood.2025031733. doi: 10.1182/blood.2025031733.
   

   >> Share

   
   

   
   BMC Cancer

4. SONG X, Fu H, Zhong X, Yu N, et al
   P300 enhances glycolysis and dox resistance in DLBCL by upregulating HK2 expression through histone lactylation.
   BMC Cancer. 2026;26:308.
   

   >> Share

   
   

   
   Bone Marrow Transplant

5. CANELO-VILASECA M, Sabbah M, Cristinelli C, Bommier C, et al
   Correction: Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?
   Bone Marrow Transplant. 2026 Mar 2. doi: 10.1038/s41409-026-02809.
   

   >> Share

   
   

   
   Br J Haematol

6. FU YC, Liu LP, Zhou YP, Yang MH, et al
   From genetic variants to therapeutic targets: A study reveals MMS19 and HLA genes in Hodgkin lymphoma pathogenesis.
   Br J Haematol. 2026 Mar 6. doi: 10.1111/bjh.70326.
   

   >> Share

   
   
7. HWANG YY, Au-Yeung R, Kwong YL
   Fibrin-associated large B-cell lymphoma occurring in an ancient retroperitoneal schwannoma.
   Br J Haematol. 2026 Mar 5. doi: 10.1111/bjh.70408.
   

   >> Share

   
   
8. TUTEJA SK, Wlodaver A, Kirschmann D, Caparelli E, et al
   Insights into the novel EEF1D::ALK fusion transcript in FISH-negative ALK-positive anaplastic large cell lymphoma.
   Br J Haematol. 2026 Mar 3. doi: 10.1111/bjh.70410.
   

   >> Share

   
   

   
   Cancer

9. DAVIES GA, Prica A, Ante Z, Liu N, et al
   Secondary primary malignancies in indolent non-Hodgkin lymphoma patients receiving frontline bendamustine-rituximab.
   Cancer. 2026;132:e70327.
   

   >> Share

   
   

   
   Haematologica

10. ABRISQUETA P, Karimi YH, Morillo D, Cordoba R, et al
    Epcoritamab plus rituximab, dexamethasone, cytarabine, oxaliplatin/carboplatin induces deep and durable responses in transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma: results from the EPCORE NHL-2 trial.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300086.
    

    >> Share

    
    
11. YANG J, Villa D, Gerrie AS, Tonseth RP, et al
    Bleomycin omission in limited-stage classic Hodgkin lymphoma with negative PET scan after two cycles of ABVD.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.289285.
    

    >> Share

    
    
12. DUAN Y, Gao H, Jin L, Yang J, et al
    Genetic and clinical characteristics of 54 pediatric lymphoma patients with variant mutation sites of UNC13D.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.287782.
    

    >> Share

    
    
13. TALAMI A, Nizzoli ME, Cappello E, Luminari S, et al
    Prognosis in marginal zone lymphoma: a comprehensive review.
    Haematologica. 2026 Mar 5. doi: 10.3324/haematol.2025.300416.
    

    >> Share

    
    

    
    Int J Radiat Oncol Biol Phys

14. DANDAPANI SV, Ahmed S, Robinson T, Advani R, et al
    Executive Summary of the American Radium Society Appropriate Use Criteria for Extranodal NK/T-Cell Lymphoma.
    Int J Radiat Oncol Biol Phys. 2026 Mar 3:S0360-3016(26)00429.
    

    >> Share

    
    

    
    Leuk Lymphoma

15. MARAGLINO AME, Sammassimo S, Clemente A, Vanazzi A, et al
    Haploidentical allogeneic hematopoietic stem cell transplantation in relapsed/refractory Hodgkin lymphoma in the era of novel agents: a single-center experience.
    Leuk Lymphoma. 2026 Mar 4:1-5. doi: 10.1080/10428194.2026.2639056.
    

    >> Share

    
    
16. WENNERAS C, Alsalihi R, Karlsson V, Lewerin C, et al
    Neoehrlichia mikurensis infection associated with lymphoma or mimicking lymphoma in two cohorts of Swedish patients.
    Leuk Lymphoma. 2026 Mar 4:1-8. doi: 10.1080/10428194.2026.2638447.
    

    >> Share

    
    
17. THIDA A, Nasirikhaneghah E, Chiu E
    Diffuse large B-cell lymphoma outcomes in an urban safety-net cohort: functional status, clinical risk, and treatment feasibility.
    Leuk Lymphoma. 2026 Mar 3:1-9. doi: 10.1080/10428194.2026.2637861.
    

    >> Share

    
    
18. WEI C, Su L, Liu L, Zhou D, et al
    Combined oral PI3Kdelta inhibitor linperlisib and HDAC inhibitor chidamide in relapsed/refractory peripheral T-cell lymphoma: a multicenter phase 1 trial.
    Leuk Lymphoma. 2026 Mar 3:1-9. doi: 10.1080/10428194.2026.2631800.
    

    >> Share

    
    
19. LIA K, Galleberg RB, Rostoft S, Jorgensen RRK, et al
    Self-reported late effects, daily functioning, and health-related quality of life in older Hodgkin lymphoma survivors - a national population-based cross-sectional survey.
    Leuk Lymphoma. 2026 Feb 28:1-11. doi: 10.1080/10428194.2026.2633180.
    

    >> Share

    
    

    
    PLoS One

20. KIM TY, Min GJ, Cho SG, Kim S, et al
    Comprehensive analysis of mortality risk factors in low-grade B-cell lymphoma.
    PLoS One. 2026;21:e0328666.
    

    >> Share

    
    
21. CHAROENRIT P, Niparuck P, Rotjanapan P
    Real-world clinical effectiveness of trimethoprim-sulfamethoxazole for primary prophylaxis of pneumocystis pneumonia in non-hodgkin lymphoma patients treated with rituximab.
    PLoS One. 2026;21:e0344273.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share